Q-omics provides the consensus-scored MIR548H3 profile across patient tissues and cancer cell-line models. MIR548H3 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR548H3 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR548H3 RNA expression shows 10,936 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight KIRC, and COAD as cancer lineages where MIR548H3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548H3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548H3 survival associations across molecular data types. MIR548H3 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548H3 RNA expression–survival associations across cancer types. High MIR548H3 expression shows unfavorable associations in KIRC, MESO and BLCA, but favorable associations in ESCA, UCS and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR548H3 RNA expression.
This table summarizes MIR548H3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548H3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548H3 shows higher tumor expression in KIRC. The KIRC box plot shows higher MIR548H3 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .042).
This table shows molecular features associated with MIR548H3 in patient tissues and cancer cell lines. In patient samples, MIR548H3 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
